{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:43Z","timestamp":1790683843357,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01180-9","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:51Z","timestamp":1788327711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0128-3463","authenticated-orcid":false,"given":"Takashi","family":"Nawata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Asami-Noyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.21037\/jtd-2024-2202","volume":"17","author":"Y Sakamori","year":"2025","unstructured":"Sakamori Y, Kawachi H, Yamoto M, Fukao A, Terashita S, Watanabe K, et al. Improvement of survival outcomes in patients with advanced-stage non-small-cell lung cancer treated with chemotherapy: a retrospective cohort study evaluating the role of immune checkpoint inhibitors. J Thorac Dis. 2025;17:4689\u2013700.","journal-title":"J Thorac Dis"},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"108752","DOI":"10.1016\/j.lungcan.2025.108752","volume":"209","author":"L Webster","year":"2025","unstructured":"Webster L, Lawton S, Kipps E, Thackray K, Tokaca N. Durvalumab in locally advanced unresectable non-small cell lung cancer\u2014Benchmarking real-world outcomes in England against published trial data. Lung Cancer. 2025;209:108752.","journal-title":"Lung Cancer"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2022.02.003","volume":"166","author":"J Naidoo","year":"2022","unstructured":"Naidoo J, Vansteenkiste JF, Faivre-Finn C, \u00d6zg\u00fcro\u011flu M, Murakami S, Hui R, et al. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: a post-hoc analysis of the PACIFIC trial. Lung Cancer. 2022;166:84\u201393.","journal-title":"Lung Cancer"},{"key":"1180_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jtho.2025.08.010","volume":"21","author":"H Kenmotsu","year":"2026","unstructured":"Kenmotsu H, Saito Y, Ninomiya K, Uematsu S, Akdemir B, Fukui A, et al. Long-term safety and effectiveness of durvalumab in unresectable Stage III NSCLC in Japan: a multicenter prospective study (AYAME). J Thorac Oncol. 2026;21:160\u201373.","journal-title":"J Thorac Oncol"},{"key":"1180_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","volume":"5","author":"H Seethapathy","year":"2020","unstructured":"Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death Ligand-1 inhibitors. Kidney Int Rep. 2020;5:1700\u20135.","journal-title":"Kidney Int Rep"},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"2569089","DOI":"10.1080\/0886022X.2025.2569089","volume":"47","author":"J Ye","year":"2025","unstructured":"Ye J, Huang J, Shao L, Wang Z. Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series. Ren Fail. 2025;47:2569089.","journal-title":"Ren Fail"},{"key":"1180_CR7","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/j.radcr.2025.01.072","volume":"20","author":"G Wang","year":"2025","unstructured":"Wang G, Yan W, Cai J, Zhang F, Lv T, Ye M. Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: a case report and literature review. Radiol Case Rep. 2025;20:2253\u20137.","journal-title":"Radiol Case Rep"},{"key":"1180_CR8","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1164\/rccm.201907-1310IM","volume":"201","author":"M Yamasaki","year":"2020","unstructured":"Yamasaki M, Taniwaki M, Kawamoto K, Matsumoto N, Hashimoto K, Nabeshima S, et al. Durvalumab-induced organizing pneumonia with a diffuse micronodular pattern in a patient with lung cancer. Am J Respir Crit Care Med. 2020;201:e52\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"1180_CR9","doi-asserted-by":"publisher","first-page":"1777694","DOI":"10.3389\/fimmu.2026.1777694","volume":"17","author":"L Jiang","year":"2026","unstructured":"Jiang L, Wang J, Xiong S, Min S, Gong N. Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective. Front Immunol. 2026;17:1777694.","journal-title":"Front Immunol"},{"key":"1180_CR10","doi-asserted-by":"publisher","first-page":"e156250","DOI":"10.1172\/JCI156250","volume":"132","author":"JW Pippin","year":"2022","unstructured":"Pippin JW, Kaverina N, Wang Y, Eng DG, Zeng Y, Tran U, et al. Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. J Clin Invest. 2022;132:e156250.","journal-title":"J Clin Invest"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12882-024-03632-9","volume":"25","author":"S Liu","year":"2024","unstructured":"Liu S, Wan Y, Hu Z, Wang Z, Liu F. Nephrotic syndrome associated with solid malignancies: a systematic review. BMC Nephrol. 2024;25:215.","journal-title":"BMC Nephrol"},{"key":"1180_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13730-025-01038-6","volume":"15","author":"R Mizoguchi","year":"2026","unstructured":"Mizoguchi R, Tashiro T, Sakakima M. Durvalumab-associated membranous nephropathy: a case report and brief literature review. CEN Case Rep. 2026;15:30.","journal-title":"CEN Case Rep"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1016\/j.ekir.2021.08.021","volume":"6","author":"MG Toda","year":"2021","unstructured":"Toda MG, Fujii K, Kato A, Yoshifuji A, Komatsu M, Amino Y, et al. Minimal change disease associated with durvalumab. Kidney Int Rep. 2021;6:2733\u20134.","journal-title":"Kidney Int Rep"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01180-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:52Z","timestamp":1788327712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01180-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01180-9","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has any conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for their anonymised information to be published in this article. Written informed consent was obtained from the patient for publication of this report.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}